[Excretion of beta-N-acetylglucosaminidase in urine in type I and type II diabetic patients with and without nephropathy].
The clinical aspects of the excretion of beta-N-acetylglucosaminidase (beta-NAG, EC 3.2.1.30) in urine of type I and type II diabetics with and without nephropathy are evaluated. Correlation between concentration of albumin and of beta-NAG activity in urine is determined and the circadian rhythm of beta-NAG excretion in urine is examined, the indication of glomerular and tubulointerstitial damage is discussed. Longitudinal studies should demonstrate, whether an increased beta-NAG activity in urine of diabetics with normoalbuminuria is an indicator of nephropathy or a predictor of nephropathy if raised albuminuria is observed.
Werle
E
E
Medizinischen Klinik und Poliklinik, Universitätsklinik Heidelberg, Bundesrepublik Deutschland.
Bostedt
A
A
Fiehn
W
W
Hasslacher
C
C
D000118:Acetylglucosaminidase / Q000652:urine*; D000328:Adult; D000419:Albuminuria / Q000175:diagnosis / Q000201:enzymology; D003124:Colorimetry / Q000295:instrumentation; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis* / Q000201:enzymology*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis* / Q000201:enzymology*; D003928:Diabetic Nephropathies / Q000175:diagnosis* / Q000201:enzymology*; D005260:Female; D006801:Humans; D007677:Kidney Function Tests / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry / Q000295:instrumentation; D012016:Reference Values
D000118:Acetylglucosaminidase
Die Ausscheidung von beta-N-Acetylglucosaminidase im Urin bei Type I- und Typ II-Diabetikern mit und ohne Nephropathie.